Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 (当归补血汤1号) in treating patients of non-small cell lung cancer at peri-operational stage

Qing-cong Du; Kui-zhong Yang; Xue-fei Sun

doi:10.1007/s11655-009-0184-y

Your Location：

Home >

Browse articles >

Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 (当归补血汤1号) in treating patients of non-small cell lung cancer at peri-operational stage

OriginalPaper | Updated：2021-08-27

- Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 (当归补血汤1号) in treating patients of non-small cell lung cancer at peri-operational stage
- Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 (当归补血汤1号) in treating patients of non-small cell lung cancer at peri-operational stage
- 中国结合医学杂志（英文版） 2009年15卷第3期页码：184-188
- Affiliations：
  
  The Fourteen Area, Wujing Shandong Zongdui Hospital,Jinan,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-009-0184-y
  中图分类号：
- 纸质出版日期：2009，
  
  网络出版日期：2009-7-2，
Scan for full text
Du, Qc., Yang, Kz. & Sun, Xf. Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 (当归补血汤1号) in treating patients of non-small cell lung cancer at peri-operational stage., Chin. J. Integr. Med. 15, 184–188 (2009). https://doi.org/10.1007/s11655-009-0184-y

Qing-cong Du, Kui-zhong Yang, Xue-fei Sun. Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 (当归补血汤1号) in treating patients of non-small cell lung cancer at peri-operational stage[J]. Chinese Journal of Integrative Medicine, 2009,15(3):184-188.
Du, Qc., Yang, Kz. & Sun, Xf. Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 (当归补血汤1号) in treating patients of non-small cell lung cancer at peri-operational stage., Chin. J. Integr. Med. 15, 184–188 (2009). https://doi.org/10.1007/s11655-009-0184-y DOI：

Qing-cong Du, Kui-zhong Yang, Xue-fei Sun. Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 (当归补血汤1号) in treating patients of non-small cell lung cancer at peri-operational stage[J]. Chinese Journal of Integrative Medicine, 2009,15(3):184-188. DOI： 10.1007/s11655-009-0184-y.

摘要

To observe the therapeutic efficacy of Danggui Buxue Decoction No.1 (当归补血汤1号

DB1) in treating patients of non-small cell lung cancer (NSCLC) at the peri-operational stage and its impact on the patients’ immune function. Eighty-two NSCLC patients were randomly assigned to two groups equally

the control group and the test group

they were given conventional treatment

while to the test group

DB1 were given additionally. The observation was conducted by testing the changes of T-lymphocyte subsets

natural killer (NK) cell activity

serum levels of immunoglobulin (IgA

IgM

IgG)

interleukin-2 (IL-2)

tumor necrosis factor α (TNF-α)

cytokeratin fragment 19 (CYFRA21-1) and carcinoembryonic antigen (CEA) in NSCLC patients before and after administration of DB1

and analyzing the patients’ general condition. The level of CD3+

CD4+

the ratio of CD4 and CD8+

IgA

IgM

IgG and IL-2 decreased in patients with NSCLC on day 1 after operation

and the level of CD8 and TNF-α increased compared to pre-operation. While the levels of CD3+

CD4+

CD4 /CD8+

NK cell activity

serum IgA

IgM

IgG

IL-2 began to elevate

CD8 and TNF-α levels began to decline in patients administered with DB1 on day 3 after the operation

earlier than patients who did not use the decoction. The level of CYFRA21-1 and CEA

was immediately decreased after operation in both groups. Applying DB1 to NSCLC patients at an early post-operational stage could alleviate the impairment and accelerate the recovery of immune function of patients to enhance their immunity. DB1 also shows an anti-tumor action to a certain degree.

Abstract

To observe the therapeutic efficacy of Danggui Buxue Decoction No.1 (当归补血汤1号

the control group and the test group

they were given conventional treatment

while to the test group

DB1 were given additionally. The observation was conducted by testing the changes of T-lymphocyte subsets

natural killer (NK) cell activity

serum levels of immunoglobulin (IgA

IgM

IgG)

interleukin-2 (IL-2)

tumor necrosis factor α (TNF-α)

cytokeratin fragment 19 (CYFRA21-1) and carcinoembryonic antigen (CEA) in NSCLC patients before and after administration of DB1

and analyzing the patients’ general condition. The level of CD3+

CD4+

the ratio of CD4 and CD8+

IgA

IgM

IgG and IL-2 decreased in patients with NSCLC on day 1 after operation

and the level of CD8 and TNF-α increased compared to pre-operation. While the levels of CD3+

CD4+

CD4 /CD8+

NK cell activity

serum IgA

IgM

IgG

IL-2 began to elevate

CD8 and TNF-α levels began to decline in patients administered with DB1 on day 3 after the operation

earlier than patients who did not use the decoction. The level of CYFRA21-1 and CEA

关键词

non-small cell lung cancerperi-operational stageimmune functionDanggui Buxue Decoction No.1immunotherapy

Keywords

non-small cell lung cancerperi-operational stageimmune functionDanggui Buxue Decoction No.1immunotherapy

references

Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007; 57:365–372.

Abiko T, Kawamura M, Izumi Y, Oyama T, Saito Y, Kobayashi K. Prediction of anti-tumour effect of thermochemotherapy with in vitro thermochemosensitivity testing for non-small cell lung cancer. Int J Hyperthermia 2007;23:267–275.

Ghiringhelli F, Menard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Reviews 2006;214: 229–238.

Schiller JH, Morgan-Ihrig C, Levitt ML. Concomitant administration of interleukin-2 plus tumor necrosis factor α in advanced non-small cell lung Cancer. Am J Clin Oncol 1995;18:47–51.

Oum Ji-Hyun, Han Juhyun, Myung Heejoon, Hleb Marija, Sharm urendra, Park Jungchan. Molecular mechanism of NFAT family proteins for differential regulation of the IL-2 and TNF-α promoters. Molecules Cells 2002;13: 77–84.

Van der Gaast A, Schoenmakers CH, Kok TC, Blijenberg BG, Splinter TA. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: CYFRA21-1. Br J Cancer 1994;69: 525–528.

Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeration subunit 19 measured by CYFRA21-1. Immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53:61–66.

Yuan SD, Ding JR, Wang SX, Cui J, Zhou JQ, Lou ZL, et al. The monitoring function of CYFRA21-1 in the treatment of non-small-cell lung cancer. Chin J Mod Med (Chin) 1997;7:9–12.

FULL TEXT LINK

More>

浏览量

394

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer

Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

Fuzheng Yiliu Granule (扶正抑瘤颗粒) inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro

Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine